MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04468cam a2200481 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
34419 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MED |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250812113208.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr |n|---||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
160111s2015 mou o 000 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
0128010762 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780128010761 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)990756593 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
LIP |
| Language of cataloging |
eng |
| Transcribing agency |
LIP |
| Modifying agency |
OCLCQ |
| -- |
ESU |
| -- |
OCLCQ |
| -- |
OCLCL |
| -- |
OCLCQ |
| -- |
OCLCL |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615/.19 |
| Assigning agency |
OCoLC |
| Edition number |
22/eng/20230216 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Di, Li. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Drug-Like Properties : |
| Remainder of title |
Concepts, Structure Design and Methods from ADME to Toxicity Optimization. |
| 246 3# - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
Drug-Like Properties - Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
2nd ed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Saint Louis : |
| Name of publisher, distributor, etc. |
Elsevier Science, |
| Date of publication, distribution, etc. |
2015. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource (582 pages) |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| 500 ## - GENERAL NOTE |
|---|
| General note |
7.1. Introduction. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Front Cover; Drug-Like Properties: Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization; Copyright; Dedication; Contents; Preface; Preface to Second Edition; Preface to First Edition; Chapter 1: Introduction; 1.1. Drug-like Properties in Drug Discovery; 1.2. Purpose of This Book; Problems; References; Chapter 2: Benefits of Property Assessment and Good Drug-Like Properties; 2.1. Introduction; 2.2. Discovery Scientists Optimize Many Properties; 2.3. Introduction to the Drug Discovery and Development Process; 2.4. Benefits of Good Drug-like Properties. |
| 505 8# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
2.4.1. Reduced Development Attrition2.4.2. More Efficient Drug Discovery; 2.4.3. More Efficient Drug Development; 2.4.4. Higher Patient Compliance; 2.4.5. Improved Biological Research in Drug Discovery; 2.4.6. Enabled Partnerships for Drug Development; 2.4.7. Human Modeling and Clinical Planning; 2.4.8. Balance of Properties and Activity; 2.5. Property Profiling in Drug Discovery; 2.6. Drug-like Property Optimization in Drug Discovery; Problems; References; Chapter 3: In Vivo Environments Affect Drug Exposure; 3.1. Introduction; 3.2. Drug Dosing; 3.3. Stomach. |
| 505 8# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
3.3.1. Gastric Acidic Degradation3.4. Intestinal Environment; 3.4.1. Dissolution Rate; 3.4.2. Solubility; 3.4.3. Permeability; 3.4.4. Intestinal Metabolism; 3.4.5. Intestinal Enzymatic Hydrolysis; 3.4.6. Absorption Enhancement in the Intestine; 3.5. Bloodstream; 3.5.1. Plasma Enzyme Hydrolysis; 3.5.2. Plasma Protein Binding; 3.5.3. Red Blood Cell Binding; 3.6. Liver; 3.6.1. Permeation into and out of Hepatocytes; 3.6.2. Hepatic Metabolism; 3.6.3. Biliary Extraction; 3.7. Kidney; 3.8. Blood-Tissue Barriers; 3.9. Tissue Distribution; 3.9.1. Nonspecific Binding in Tissue. |
| 505 8# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
3.10. Consequences of Chirality3.11. Overview of in vivo Challenges to Drug Exposure; Problems; References; Chapter 4: Prediction Rules for Rapid Property Profiling from Structure; 4.1. Introduction; 4.2. General Concepts for Prediction Rules; 4.3. Rule of 5; 4.4. Veber Rules; 4.5. Waring Rules; 4.6. Golden Triangle; 4.7. Other Predictive Rules; 4.8. Application of Rules for Compound Assessment; 4.9. Applications of Predictive Rules; Problems; References; Chapter 5: Lipophilicity; 5.1. Lipophilicity Fundamentals; 5.2. Lipophilicity Effects. |
| 505 8# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
5.3. Lipophilicity Case Studies and Structure Modification5.3.1. Lipophilicity Modification for Biological Activity; 5.3.2. Lipophilicity Modification for Pharmacokinetics; 5.3.3. Lipophilicity Modification for Toxicity; Problems; References; Chapter 6: pKa; 6.1. pKa Fundamentals; 6.2. pKa Effects; 6.2.1. pKa Affects Efficacy; 6.2.2. pKa Affects Pharmacokinetics; 6.2.3. pKa Affects Toxicity; 6.3. pKa Case Studies; 6.3.1. pKa and Activity Examples; 6.3.2. pKa and Pharmacokinetics Examples; 6.4. Structure Modification Strategies for pKa; Problems; References; Chapter 7: Solubility. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English. |
| 588 0# - SOURCE OF DESCRIPTION NOTE |
|---|
| Source of description note |
Print version record. |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacy, Therapeutics, & Pharmacology. |
| 650 #4 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Health & Biological Sciences. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacy, Therapeutics, & Pharmacology. |
| Source of heading or term |
hilcc |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Health & Biological Sciences. |
| Source of heading or term |
hilcc |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kerns, Edward H. |
| 758 ## - RESOURCE IDENTIFIER |
|---|
| Relationship information |
has work: |
| Label |
Drug-like properties (Text) |
| Real World Object URI |
https://id.oclc.org/worldcat/entity/E39PCGK43gt4xT4bqrrprbkX7d |
| Relationship |
https://id.oclc.org/worldcat/ontology/hasWork |
| 936 ## - OCLC/CONSER MISCELLANEOUS DATA (OCLC); PIECE USED FOR CATALOGING (pre-AACR2) (RLIN) |
|---|
| OCLC control number(s) of parallel record(s) (OCLC); Piece used for cataloging, PUC (RLIN) |
BATCHLOAD |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
كتاب |
| Suppress in OPAC |
No |
| 948 ## - LOCAL PROCESSING INFORMATION (OCLC); SERIES PART DESIGNATOR (RLIN) |
|---|
| h (OCLC) |
NO HOLDINGS IN IQMCL - 1 OTHER HOLDINGS |
